Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression

Li,Liang; Xu,Ying; Wang,Binquan

doi:10.3892/ol.2014.2834

Liriodenine induces the apoptosis of human laryngocarcinoma cells via the upregulation of p53 expression

Authors:
- Liang Li
- Ying Xu
- Binquan Wang
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China, Department of Otolaryngology, Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: December 29, 2014 https://doi.org/10.3892/ol.2014.2834
Pages: 1121-1127
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Laryngocarcinoma is one of the most aggressive cancers that affects the head and neck region. The survival rate of patients with laryngocarcinoma is low due to late metastases and the resistance of the disease to chemotherapy and radiotherapy. Liriodenine, an alkaloid extracted from a number of plant species, has demonstrated antitumor effects on multiple types of cancer. However, the effects of liriodenine upon laryngocarcinoma, and the underlying mechanisms, are yet to be elucidated. The present study therefore investigated the potential antitumor effects of liriodenine on HEp‑2 human laryngocarcinoma cells in vitro and HEp‑2‑implanted nude mice in vivo. Liriodenine induced significant apoptosis and inhibition of cell migration in the HEp‑2 cells. Furthermore, the rate of tumor growth in the HEp‑2‑implanted nude mice was inhibited by the administration of liriodenine. The potential mechanism underlying the antitumor effects of liriodenine may result from an upregulative effect upon p53 expression, which ultimately induces cellular apoptosis. By contrast, the downregulation of p53 significantly reduced the antitumor effects of liriodenine. Together, these results suggest that liriodenine exhibits potent antitumor activities in laryngocarcinoma HEp‑2 cells, in vitro and in vivo, via the upregulation of p53 expression. Liriodenine may therefore be a potential therapy for the treatment of laryngocarcinoma.

View Figures

View References

1	Nix P, Lind M, Greenman J, Stafford N and Cawkwell L: Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol. 15:797–801. 2004. View Article : Google Scholar : PubMed/NCBI
2	Cann CI, Fried MP and Rothman KJ: Epidemiology of squamous cell cancer of the head and neck. Otolaryngol Clin North Am. 18:367–388. 1985.PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
4	American Society of Clinical Oncology. Pfister DG, Laurie SA, Weinstein GS, et al: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 24:3693–3704. 2006. View Article : Google Scholar : PubMed/NCBI
5	Chatrath P, Scott IS, Morris LS, et al: Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. Br J Cancer. 95:314–321. 2006. View Article : Google Scholar : PubMed/NCBI
6	Taguchi T and Tsukuda M: Attempts to improve organ preservation in patients with squamous cell carcinoma of the head and neck. Gan To Kagaku Ryoho. 32:2030–2034. 2005.(In Japanese). PubMed/NCBI
7	Warthen D, Gooden EL and Jacobson M: Tumor inhibitors: liriodenine, a cytotoxic alkaloid from Annona glabra. J Pharm Sci. 58:637–638. 1969. View Article : Google Scholar : PubMed/NCBI
8	Bentley KW: Beta-phenylethylamines and the isoquinoline alkaloids. Nat Prod Rep. 18:148–170. 2001. View Article : Google Scholar : PubMed/NCBI
9	Hsieh TJ, Liu TZ, Chern CL, et al: Liriodenine inhibits the proliferation of human hepatoma cell lines by blocking cell cycle progression and nitric oxide-mediated activation of p53 expression. Food Chem Toxicol. 43:1117–1126. 2005. View Article : Google Scholar : PubMed/NCBI
10	Clark AM, Watson ES, Ashfaq MK and Hufford CD: In vivo efficacy of antifungal oxoaporphine alkaloids in experimental disseminated candidiasis. Pharm Res. 4:495–498. 1987. View Article : Google Scholar : PubMed/NCBI
11	Hufford CD, Funderburk MJ, Morgan JM and Robertson LW: Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera L. J Pharm Sci. 64:789–792. 1975. View Article : Google Scholar : PubMed/NCBI
12	Chang GJ, Wu MH, Wu YC and Su MJ: Electrophysiological mechanisms for antiarrhythmic efficacy and positive inotropy of liriodenine, a natural aporphine alkaloid from Fissistigma glaucescens. Br J Pharmacol. 118:1571–1583. 1996. View Article : Google Scholar : PubMed/NCBI
13	Khamis S, Bibby MC, Brown JE, et al: Phytochemistry and preliminary biological evaluation of Cyathostemma argenteum, a malaysian plant used traditionally for the treatment of breast cancer. Phytother Res. 18:507–510. 2004. View Article : Google Scholar : PubMed/NCBI
14	Chiu CC, Chou HL, Wu PF, et al: Bio-functional constituents from the stems of Liriodendron tulipifera. Molecules. 17:4357–4372. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chang HC, Chang FR, Wu YC and Lai YH: Anti-cancer effect of liriodenine on human lung cancer cells. Kaohsiung J Med Sci. 20:365–371. 2004. View Article : Google Scholar : PubMed/NCBI
16	Guo Z, Vangapandu S, Sindelar RW, Walker LA and Sindelar RD: Biologically active quassinoids and their chemistry: potential leads for drug design. Curr Med Chem. 12:173–190. 2005. View Article : Google Scholar : PubMed/NCBI
17	Chen ZF, Liu YC, Peng Y, et al: Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine. J Biol Inorg Chem. 17:247–261. 2012. View Article : Google Scholar
18	Wu YC, Duh CY, Wang SK, Chen KS and Yang TH: Two new natural azafluorene alkaloids and a cytotoxic aporphine alkaloid from Polyalthia longifolia. J Nat Prod. 53:1327–1331. 1990. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Gao L, Li Y, Chen H and Sun Z: Nifedipine protects INS-1 β-cell from high glucose-induced ER stress and apoptosis. Int J Mol Sci. 12:7569–7580. 2011. View Article : Google Scholar
20	Wu J, Sun P, Zhang X, et al: Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis. J Cell Biochem. 113:1152–1158. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sun P, Wang T, Zhou Y, et al: DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-cells dysfunction in db/db mice. PLoS One. 8:e667442013. View Article : Google Scholar
22	Levine AJ and Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 9:749–758. 2009. View Article : Google Scholar : PubMed/NCBI
23	Soengas MS, Alarcón RM, Yoshida H, et al: Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:156–159. 1999. View Article : Google Scholar : PubMed/NCBI
24	Schultz RM, Merriman RL, Toth JE, et al: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res. 5:223–228. 1993.PubMed/NCBI
25	Belotti D, Paganoni P, Manenti L, et al: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63:5224–5229. 2003.PubMed/NCBI
26	Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
27	Akkiprik M, Sonmez O, Gulluoglu BM, et al: Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res. 15:359–368. 2009. View Article : Google Scholar
28	Jiang LY, Lian M, Wang H, Fang JG and Wang Q: Inhibitory effects of 5-aza-2′-deoxycytidine and trichostatin A in combination with p53-expressing adenovirus on human laryngocarcinoma cells. Chin J Cancer Res. 24:232–237. 2012. View Article : Google Scholar
29	Zhao F, Huang W, Ousman T, et al: Triptolide induces growth inhibition and apoptosis of human laryngocarcinoma cells by enhancing p53 activities and suppressing E6-mediated p53 degradation. PLoS One. 8:e807842013. View Article : Google Scholar : PubMed/NCBI
30	Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 9:714–723. 2009.PubMed/NCBI
31	Junttila MR and Evan GI: p53 - a Jack of all trades but master of none. Nat Rev Cancer. 9:821–829. 2009. View Article : Google Scholar : PubMed/NCBI
32	Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ and Oudejans JJ: Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol. 220:509–520. 2010. View Article : Google Scholar : PubMed/NCBI
33	Roth JA, Swisher SG and Meyn RE: p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park). 13(Suppl 5): 148–154. 1999.
34	Bascones-Martínez A, Rodríguez-Gutierrez C, Rodríguez-Gómez E, et al: Evaluation of p53, caspase-3, Bcl-2, and Ki-67 markers in oral squamous cell carcinoma and premalignant epithelium in a sample from Alava Province (Spain). Med Oral Patol Oral Cir Bucal. 18:e846–e850. 2013. View Article : Google Scholar : PubMed/NCBI